抗体偶联药物的研究进展  

Research Progress of Antibody-Drug Conjugate

作　　者：李玲[1] 杨雪[1] 刘根利 袁胜利[1] 

机构地区：[1]青岛大学附属青岛市市立医院肿瘤科,山东 青岛 [2]大连医科大学附属青岛市市立医院肿瘤科,山东 青岛

出　　处：《临床医学进展》2021年第9期4135-4143,共9页Advances in Clinical Medicine

摘　　要：抗体偶联药物(antibody-drug conjugate, ADC)是一类由靶点特异的单克隆抗体(mAb)及具有强效细胞毒性的小分子药物(payload)通过生物活性连接子(linker)偶联而成的新型生物药物。ADC可以将高效的细胞毒药物直接递送到肿瘤细胞,同时对正常组织的毒性降至最低,这种对靶点的准确识别性及非癌细胞不受影响性,极大提高了药效并减少了毒副反应。迄今为止,全球已开展的ADC临床研究已接近200项,其中获美国食品药品监督管理局(FDA)批准的ADC有10个。在本文中,综述了ADC的发展过程、组成部分以及获批的10个ADC的临床试验及未来发展方向。Antibody-drug conjugate (ADC) is a type of new biologic drug couple target-specific monoclonal antibody (mAb) and small cytotoxic drug with strong cytotoxicity (payload) by a biologically active linker (linker). ADC can deliver high-efficiency cytotoxic drugs directly to tumor cells while minimizing the toxicity to normal tissues. This specificity is unaffected to the non-tumor cell, which greatly improves the efficacy and reduces toxicity. So far, nearly 200 ADC clinical studies have been carried out worldwide, of which 10 ADCs have been approved by the Food and Drug Administration (FDA). In this article, the development process and components of ADC are reviewed, as well as the clinical trials and future development directions of 10 ADCs approved.

关 键 词：抗体偶联药物 组成部分 疗效 临床试验 

分 类 号：R73[医药卫生—肿瘤]